February 11, 2020 / 12:40 PM / 16 days ago

BRIEF-Myriad Submits sPMA For Mychoice CDx With Lynparza In First-Line Advanced Ovarian Cancer Maintenance Therapy

Feb 11 (Reuters) - Myriad Genetics Inc:

* MYRIAD SUBMITS SPMA FOR MYCHOICE CDX WITH LYNPARZA IN FIRST-LINE MAINTENANCE THERAPY IN ADVANCED OVARIAN CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below